BNC105: Additional Phase II data

Bionomics said second-line treatment with 16 mg/m 2 IV BNC105 missed the primary endpoint of ORR in a single-arm, open-label, Australian Phase II trial in 30 patients with MPM who progressed after first-line chemotherapy with Alimta pemetrexed and cisplatin. Specifically, there was 1 (3%) complete response and 13 (43%) cases of stable disease. Median PFS was 1.5 months and median OS was 8.7 months. There were no significant hematologic, biochemical, peripheral neurotoxic or cardiac adverse events reported. There were 2 deaths that occurred during the trial - 1 due to stroke and 1 due to pneumonia and respiratory failure. Patients received BNC105P, the inactive prodrug of BNC105 that is metabolized into BNC105 within the body, on days 1 and 8 of a 21-day cycle. Data were presented at the American Society of Clinical Oncology meeting in Chicago. ...